Chief Financial Officer
Christopher Sullivan is the CFO and Head of Investor Relations at Avalo Therapeutics, managing financial strategy and investor communications. He supports key initiatives including the Phase 2 LOTUS trial for AVTX-009. With a tenure of approximately four years, his compensation totals around $2.93 m